Разработка методики оптимизации данных для неразрушающего контроля прочности бетона по параметрам электрического отклика на ударное воздействие

The article presents the results of investigation to improve the method of non-destructive testing of concrete strength by the parameters of electric response to impact excitation. The Electric response parameters of concrete samples with the same composition in size 100x100x100mm were studied. It is shown that the use of linear filtering procedure reduces the variance of diagnostic electric parameter to determine the strength of concrete

Examination of carbon partitioning into austenite during tempering of bainite

The redistribution of carbon after tempering of a novel nanocrystalline bainitic steel consisting of a mixture of supersaturated ferrite and retained austenite has been analyzed by atom probe tomography. No direct evidence supporting the additional carbon enrichment of austenite beyond that initially achieved during the bainite heat treatment was obtained during subsequent tempering of this high carbon, high silicon steel.The authors gratefully acknowledge the support of the Research Fund for Coal and Steel and the Spanish Ministry of Science and Innovation for funding this research under the contracts RFSR-CT-2008-00022 and MAT2007 – 63873, respectively. Research at the Oak Ridge National Laboratory SHaRE User Facility was sponsored by the Scientific User Facilities Division, Office of Basic Energy Sciences, U.S. Department of Energy. A.J. Clarke gratefully acknowledges support from Los Alamos National Security, LLC, operator of the Los Alamos National Laboratory under contract number DE-AC52-06NA25396 with the U.S. Department of Energy and the Advanced Steel Processing and Products Research Center, a National Science Foundation Industry/University Cooperative Research Center at the Colorado School of Mines and the Inter-American Materials Collaboration ProgramPeer reviewe

Bağ bozumu

Yesarizade Mahmut Esat'ın Son Saat'te tefrika edilen Bağ Bozumu adlı roman

Isradipine therapy in Cacna1dIle772Met/+ mice ameliorates primary aldosteronism and neurologic abnormalities

Somatic gain-of-function mutations in the L-type calcium channel CaV1.3 (CACNA1D gene) cause adrenal aldosterone-producing adenomas and micronodules. De novo germline mutations are found in a syndrome of primary aldosteronism, seizures, and neurologic abnormalities (PASNA) as well as in autism spectrum disorder. Using CRISPR/Cas9, we here generated mice with a Cacna1d gain-of-function mutation found in both adenomas and PASNA syndrome (Cacna1dIle772Met/+). These mice show reduced body weight and increased mortality from weaning to approximately 100 days of age. Male mice do not breed, likely due to neuromotor impairment, and the offspring of female mice die perinatally, likely due to lack of maternal care. Mice generated by in vitro fertilization showed elevated intracellular calcium in the aldosterone-producing zona glomerulosa, an elevated aldosterone/renin ratio, and persistently elevated serum aldosterone on a high-salt diet as signs of primary aldosteronism. Anesthesia with ketamine and xylazine induced tonic-clonic seizures. Neurologic abnormalities included hyperlocomotion, impaired performance in the rotarod test, impaired nest building, and slight changes in social behavior. Intracellular calcium in the zona glomerulosa, aldosterone levels, and rotarod performance responded to treatment with the calcium channel blocker isradipine, with implications for the therapy of patients with aldosterone-producing lesions and with PASNA syndrome

Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice: Conditional DREADD Mice

DREADDs, designer receptors exclusively activated by designer drugs, are engineered G protein-coupled receptors (GPCR) which can precisely control GPCR signaling pathways (for example, Gq, Gs and Gi). This chemogenetic technology for control of GPCR signaling has been successfully applied in a variety of in vivo studies, including in mice, to remotely control GPCR signaling, for example, in neurons, glia cells, pancreatic beta-cells, or cancer cells. In order to fully explore the in vivo applications of the DREADD technology we generated hM3Dq and hM4Di strains of mice which allow for Cre recombinase-mediated restricted expression of these pathway-selective DREADDs. With the many Cre driver lines now available, these DREADD lines will be applicable to studying a wide array of research and preclinical questions

Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers

Introduction: Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B/D. We investigated the drug-drug interaction potential and pharmacokinetics of high-dose subcutaneous bulevirtide (5 mg twice daily) with organic anion transporting polypeptide 1B1 (OATP1B1) and cytochrome P450 (CYP) 3A4.Methods: This was a single-center, open-label, fixed-sequence drug-drug interaction trial in 19 healthy volunteers. Before and at bulevirtide steady state, participants ingested a single 40 mg dose of pravastatin. A midazolam microdose was applied to quantify CYP3A4 activity.Results: At bulevirtide steady state, pravastatin area under the concentration-time curve (AUC0–∞) increased 1.32-fold (90% CI 1.08-1.61). The 5 mg bulevirtide twice-daily treatment resulted in a mean AUC0-12 of 1210 h*ng/ml (95% CI 1040-1408) and remained essentially unchanged under the influence of pravastatin. CYP3A4 activity did not change to a clinically relevant extent. As expected, total bile acids increased substantially (35-fold) compared to baseline during bulevirtide treatment. All study medication was well tolerated.Discussion: The study demonstrated that high-dose bulevirtide inhibited OATP1B-mediated hepatic uptake of the marker substrate pravastatin but the extent is considered clinically not relevant. Changes in CYP3A4 activity were also not clinically relevant. In conclusion, this study suggests that OATP1B substrate drugs as well as CYP3A4 substrates may safely be used without dose adjustment in patients treated with bulevirtide. However, in patients using high statin doses and where concomitant factors potentially further increase statin exposure, caution may be required when using bulevirtide

Formalized classification of semi-dry grasslands in central and eastern Europe

European semi-dry grasslands are among the most species-rich vegetation types in the northern hemisphere and form an important part of the habitat mosaics in the forest-steppe zone. However. there is no comprehensive evaluation of the variation in their composition and the phytosocio-logical classification of these grasslands. For the syntaxonomic revision, we used a dataset of 34,173 vegetation plot records (releves) from central and eastern Europe. which were assigned to the class Fesiuco-Bromeiea using the diagnostic species listed in the EuroVegChecklist. To determine the diagnostic species of the orders, we used a TWINSPAN classification of the whole dataset. Of the total dataset, 15,449 releves were assigned to the order Brachypodietalia pinnati. which corresponds to semi-dry grasslands. This subset was again classified using TWINSPAN. Formal definitions of the following alliances were established: Mesobromion erecti, Cirsio-Brachypodion pinnati (incl. Fragario-Trifolion montani. Agrosiio-Avenulion schellianae, Scabioso ochroleucae-Poion angustifoliae and Adonido vernalis-Stipion iirsae), Scorzonerion villosae and Chrysopogono-Danshonion. Another alliance, Armerion elongatae (=Koelerio-Phleion phleoidis p.p.). is transitional towards the class Koelerio-Corynephoreiea and its status needs further evaluation. We also established formal definitions of all of the associations of Mesobromion and Cirsio-Brachypodion within the area studied. Associations were identified using (i) a TWINSPAN classification of the whole order, (ii) TWINSPAN classifications of regionally restricted data sets (usually all Brachypodietalia plots in one country) and (iii) existing national classification schemes. All formal definitions were written in the expert system language of the JUICE program. To obtain a more complete picture of the floristic similarities and gradients. we performed a DCA ordination of the associations. Our results revealed that meadow steppes in the forest-steppe zone in eastern Europe are very similar to semi-dry grasslands in central Europe

2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.

BACKGROUND: A 1-year follow-up, polymer-free metallic stent coated with biolimus-A9 followed by 1-month dual antiplatelet therapy is safer and more effective than a bare-metal stent (BMS) for patients with high risk of bleeding. OBJECTIVES: This study analyzed 2-year outcomes to determine whether these benefits are maintained. METHODS: In a prospective, multicenter, double-blind trial, we randomized 2,466 high bleeding risk patients to receive a drug-coated stent (DCS) or a BMS followed by 1-month dual antiplatelet therapy. The primary safety endpoint was a composite of cardiac death, myocardial infarction, or stent thrombosis. The primary efficacy endpoint was clinically driven target lesion revascularization. RESULTS: At 2 years, the primary safety endpoint had occurred in 147 DCS and 180 BMS patients (15.3%) (hazard ratio: 0.80; 95% confidence interval: 0.64 to 0.99; p = 0.039). Clinically driven target lesion revascularization occurred for 77 DCS and 136 BMS patients (12.0%) (hazard ratio: 0.54; 95% confidence interval: 0.41 to 0.72; p 75 years, anemia, raised plasma creatinine, and planned long-term anticoagulation. Correlates of the primary safety endpoint were age, anemia, congestive heart failure, multivessel disease, number of stents implanted, and use of a BMS rather than a DCS. CONCLUSIONS: Safety and efficacy benefits of DCS over BMS were maintained for 2 years in high bleeding risk patients. Rates of major bleeding and coronary thrombotic events were no different and were associated with a substantial and comparable mortality risk. (A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding [LEADERS FREE]; NCT01623180)